Revised MRPs of 1,364 anti-cancer formulations come into effect; consumers to save ₹3,540 crore/year

The Indian government has implemented revised Maximum Retail Prices for 1,364 anti-cancer drug formulations, aiming to save consumers over ₹3,500 crore annually. While the move is a significant price reduction, experts argue that structural reforms are still needed to ensure long-term affordability in cancer care.
Why it matters
This policy directly impacts the financial burden of life-saving treatments for millions of patients in India.
New Delhi Revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer formulations have come into effect from Monday (November 9, 2026), a move projected to save consumers an estimated ₹3,540.38 crore annually, according to an official release. Who decides the cost of medicines in India? storyline 1 Will the price caps on cancer drugs help bring down the cost of treatment? Will the price caps on cancer drugs help bring down the cost of treatment? For cancer patients in India, the struggle to stay alive is as much about the disease as about the arithmetic of fighting it. Experts call the government’s price caps a tokenistic, short-term measure. Patients will not benefit unless structural changes including tackling pricing at the manufacturing end, and large-scale government procurement to stabilise prices are put in place Will capping trade margins on 137 non-scheduled anti-cancer drugs bring down the overall cost of treatment?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in